+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year

IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.

• Operating surplus of 255 K€ in the second half of 2019, -70 K€ over the entire year

• Sustained increase in activity during 2019: +20%

– Initiation of SeqOIA sequencing platform operations

– Increase in activities carried out at the Institut Pasteur

• Acceleration of software sales activities focusing on the interpretation of genomic data

• Implementation of measures to ensure continuity of operations despite the COVID-19 pandemic with maintenance of genomic activity and preservation of financial resources

Click here to view press release